Will CRISPR’s November 9 gene-editing results show triglycerides cut by at least 70%?

Question

This market will resolve YES if at least one prespecified CTX310 dose cohort containing three or more evaluable participants reports a mean triglyceride reduction from baseline of at least 70% at its first reported scheduled assessment on or after day 28 in the results presented for the CTX310 phase 1b severe-hypertriglyceridemia study at the American Heart Association Scientific Sessions 2026. The official programme schedules the relevant presentation on November 9 in Chicago. This is a questio

Problyx · Accepted Answer

Yes — the community forecast puts this at 57%.

Problyx · Answer

No — the community forecast puts this at 43%.